
Canbex Therapeutics hires chief medical officer
pharmafile | March 5, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Canbex Therapeutics
UK biotech firm Canbex Therapeutics has appointed former Lilly head Dr Alberto Lledó as its new chief medical officer (CMO).
Lledó is a senior consultant neurologist at Clínica Creu Blanca in Barcelona, but spent 16 years at Eli Lilly in roles comprising global senior medical advisor and CNS clinical research physician for Europe.
Lledó will take over as CMO from Dr Miroslav Ravic, and Dr Jesse Schulman, chief executive of Canbex, said: “Finding a candidate of Dr Lledó’s broad experience and deep expertise meets a key corporate priority for Canbex as we prepare for Proof of Concept trials.”
Schulman added: “His wealth of expertise in Neuroscience, in clinical practice with multiple sclerosis patients and in clinical development will all play a key role in the development of VSN16R.”






